Related Experiment Video
Updated: Jul 19, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Therapy for Gaucher disease: don't stop thinking about tomorrow
Ellen Sidransky1, Mary E LaMarca, Edward I Ginns
1Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Building 35, Room 1A213, 35 Convent Drive, MSC 3708, Bethesda, MD 20892, USA. sidranse@mail.nih.gov
Molecular Genetics and Metabolism
|November 7, 2006
Summary
Enzyme replacement therapy is effective for Gaucher disease, but ongoing research into gene, substrate reduction, and chaperone therapies is crucial. Continued innovation in treatments will benefit patients with Gaucher disease and other lysosomal disorders.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Enzyme replacement therapy (ERT) is a standard treatment for Gaucher disease.
- While ERT is effective and safe, further therapeutic advancements are needed.
Purpose of the Study:
- To review current and emerging treatment strategies for Gaucher disease.
- To highlight the importance of continuous improvement in lysosomal disorder therapies.
Main Methods:
- Literature review of existing and novel therapeutic approaches.
- Analysis of potential benefits and challenges of different treatment modalities.
Main Results:
- Enzyme replacement therapy demonstrates efficacy and safety in Gaucher disease management.
- Gene therapy, substrate reduction therapy, and chaperone therapy are promising alternatives.
- Improvements in existing enzyme therapy can also enhance clinical outcomes.
Conclusions:
- Despite the success of ERT, complacency is unwarranted.
- Further development of novel treatments and optimization of current therapies are essential for Gaucher disease and other lysosomal disorders.
- Future strategies should focus on improving efficacy, cost, safety, and availability.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...